AcadeMab Biomedical Inc.
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
AcadeMab’s pipeline includes AM‑928, an anti‑EpCAM monoclonal antibody for solid tumors; AM‑168, an anti‑HER3 antibody for patients resistant to EGFR or HER2 therapies; and SB‑001, a monoclonal antibody targeting COVID‑19.
In parallel, AcadeMab is develo
In parallel, AcadeMab is develo
Founded Year
2020
Unified Business No.
83769127
Status
Active
Number of Employees
0
Total Paid-in
Capital
506,960,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
AcadeMab Biomedical Inc., founded in 2020, is a Taiwan‑based biotech company dedicated to novel antibody therapeutics and mRNA vaccine development. By integrating advanced antibody discovery platforms with mRNA-LNP technology, AcadeMab aims to tackle unmet clinical needs through a dual‑engine approach.
